Third Pole
- Company typePrivate
- Founded2014
- HeadquartersWaltham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Third Pole firmographics
Firmographics- Name
- Third Pole
- Legal name
- Third Pole, Inc.
- Website
- https://pole3.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Third Pole industry classification
Industry- Product category
- Inhaled Nitric Oxide Therapy Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE)
- akta.pro secondary industries
- Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK), Wearable Injectors & On-Body Delivery Systems (HLAHAIAE), Medical & Healthcare Gases (IMAEACAF)
Keywords
Where Third Pole is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Third Pole business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- eNOcare™ Hospital Device Sales: Sale or licensing of the eNOcare™ portable in-hospital nitric oxide delivery device into the existing $600M iNO hospital market. The device targets large hospitals and developed markets where iNO is already established for treating newborn respiratory failure and post-cardiac surgery patients.
- eNOfit™ Wearable/Outpatient Device Sales: Sale of the miniaturized wearable eNOfit™ device targeting the outpatient/home market for patients with severe COPD, ILD, and pulmonary hypertension. The device targets 1.2M–1.5M patients struggling with chronic lung diseases, with a commercial opportunity estimated to exceed $12B annually.
- NO Generation Technology Licensing: The broadly patented NO generation technology may be licensed to other companies. The company has expressed openness to partnerships for creating, developing, and commercializing cardio-pulmonary products that expand current markets and create new markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | No publicly disclosed pricing tiers available for Third Pole's eNOfit™ or eNOcare™ devices. |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Third Pole product offering
Product offeringCore offering
Third Pole develops tankless, on-demand inhaled nitric oxide (iNO) generation and delivery devices for hospital and ambulatory use. Its two investigational platforms—eNOcare™ (a portable in-hospital device) and eNOfit™ (a miniaturized, ~2-pound wearable device)—produce therapeutic nitric oxide from ambient air and electricity using patented pulsed electrical discharge technology, eliminating the need for compressed gas cylinders.
Product overview
Third Pole Therapeutics offers two distinct medical device platforms for inhaled nitric oxide (iNO) therapy: eNOfit™ (a miniaturized, two-pound wearable device for home and travel use) and eNOcare™ (a lightweight portable in-hospital device). Both platforms use proprietary technology that generates NO on-demand by combining electricity and ambient air, creating a 'make it and take it' therapy that eliminates the need for compressed gas tanks. The platforms are designed to serve different care settings—the eNOfit™ for ambulatory/outpatient use and eNOcare™ for hospital use—while sharing the same core tankless NO generation technology. Both products are investigational and not currently FDA cleared or approved.
Differentiator
Problem solved
Functional benefit
Brands
- eNOfit: Miniaturized wearable device for home and travel use, providing portable inhaled nitric oxide therapy for patients with pulmonary hypertension associated with ILD and COPD.
- eNOcare
Products and services
- eNOfit™ A miniaturized, portable inhaled nitric oxide generator and delivery system designed for ambulatory/outpatient use. The approximately two-pound wearable device generates NO on-demand from electricity and ambient air, providing treatment for patients with pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD) and COPD. Currently investigational, not yet FDA cleared or approved.
- eNOcare™ A lightweight portable in-hospital device for delivering inhaled nitric oxide (iNO) therapy. Designed to increase access and affordability of nitric oxide treatment in hospital settings, generating NO on-demand from electricity and ambient air. Received FDA breakthrough designation; targeted for FDA submission as of 2022-2023. Investigational, not yet FDA cleared or approved.
Quantifiable outcome
- Market opportunity for eNOfit™ estimated to exceed $12B annually
- +6 more outcomes
Companies that use Third Pole
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Third Pole technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Third Pole partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- U.S. Patent and Trademark Office (USPTO)coreThe USPTO issued new U.S. patents covering Third Pole's innovative general and portable inhaled nitric oxide delivery systems, providing the company with broad intellectual property protection for its tankless iNO technology.
- Actelion Pharmaceuticals Ltd (Janssen Pharmaceutical Company of Johnson & Johnson)coreThird Pole entered into a strategic collaboration with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson, to advance inhaled nitric oxide therapy. This collaboration was announced March 26, 2019. Actelion is a leading pharmaceutical company in pulmonary hypertension, making this a strategically aligned partnership for market expansion.
- Boston Biomedical Innovation Center (B-BIC)minorErin McKenna, Board Observer representing Partners/MGH, is a leader in the Boston Biomedical Innovation Center, a life sciences accelerator funded by the NIH. This connection facilitates NIH-funded innovation support for Third Pole.
- Johnson & Johnson Innovation (JLABS @ M2D2)minorThird Pole won the Johnson & Johnson Innovation JLABS @ M2D2 QuickFire Challenge in May 2017, receiving recognition and support from J&J's innovation ecosystem for its lighter nitric oxide system.
- Massachusetts General Hospital (MGH)coreThird Pole's core technology is based on innovations developed by founder Warren Zapol at Harvard's Massachusetts General Hospital. The company maintains ongoing R&D and clinical collaborations with MGH, with Erin McKenna representing Partners/MGH on Third Pole's board. Clinical studies for eNOfit™ are conducted with MGH-affiliated investigators.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Third Pole competitors and assessment
Company assessmentEmerging players
- Aerogen: Aerogen specializes in aerosol drug delivery systems for ventilated and spontaneously breathing patients in the hospital setting. It is an emerging player in inhaled respiratory drug/device delivery, comparable in technology category to Third Pole's hospital iNO delivery device.
- Pulmonx: Pulmonx develops interventional treatments for severe COPD and emphysema (Zephyr® valves). It is an emerging player in the same severe-COPD patient population Third Pole targets with eNOfit™, representing a different therapeutic modality for overlapping indications.
- Bellerophon Therapeutics: Bellerophon develops INOpulse®, a proprietary inhaled nitric oxide delivery system targeting pulmonary hypertension and cardiopulmonary diseases. It targets overlapping patient populations (PH-ILD, PH-COPD) with Third Pole's eNOfit™ and is a relevant emerging competitor in ambulatory iNO.
Broad incumbents
- ResMed: ResMed is a global leader in respiratory care devices including portable oxygen and ventilation equipment for COPD and chronic lung disease patients. It represents a broader incumbent in portable/home respiratory therapy adjacent to Third Pole's eNOfit™ market.
- Philips Respironics: Philips Respironics manufactures hospital and home respiratory care equipment, including ventilators and oxygen concentrators. It is a broad incumbent in the respiratory device space where Third Pole's eNOcare™ and eNOfit™ compete for hospital and home-care share.
- United Therapeutics: United Therapeutics markets Tyvaso® (inhaled treprostinil) and other therapies for pulmonary arterial hypertension and PH-ILD. It is a broad incumbent in the same therapeutic indication space Third Pole's eNOfit™ targets, representing an established alternative therapy.
- Inogen: Inogen is a leader in portable oxygen concentrators for chronic respiratory disease patients (COPD, ILD) in the home/ambulatory setting. It addresses the same patient population Third Pole targets with eNOfit™, but with oxygen rather than nitric oxide, and represents a relevant portable respiratory device comparable.
- Mallinckrodt Pharmaceuticals (INO Therapeutics): Mallinckrodt owns INOmax, the dominant inhaled nitric oxide therapy (>USD 400M annual revenue before acquisition for $2.3B). It is the entrenched incumbent in the hospital iNO market that Third Pole must displace or differentiate against.
Direct peers
- Vero Biotech: Vero Biotech has developed and received FDA approval for Genosyl®, a tankless inhaled nitric oxide delivery system. It is the most direct competitive threat to Third Pole, addressing the same hospital iNO market with a similar on-demand generation approach.
- Beyond Air: Beyond Air develops nitric oxide-based therapies for respiratory and infectious diseases, including LungFit® systems. It overlaps with Third Pole on inhaled NO generation technology and pulmonary indications, though it has focused more on hospital-based anti-infective applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Third Pole social profiles
Digital presenceThird Pole compliance and trust
Trust signalCompliance1 record
Third Pole financial estimates
Financial estimateRevenue estimate
Valuation estimate
Third Pole leadership team
Management profileNumber of profiles
Profiles7 records
Third Pole funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Third Pole M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Third Pole
What does Third Pole do?
Third Pole develops tankless, on-demand inhaled nitric oxide (iNO) generation and delivery devices for hospital and ambulatory use. Its two investigational platforms—eNOcare™ (a portable in-hospital device) and eNOfit™ (a miniaturized, ~2-pound wearable device)—produce therapeutic nitric oxide from ambient air and electricity using patented pulsed electrical discharge technology, eliminating the need for compressed gas cylinders.
Is Third Pole a public or private company?
Third Pole is a private company. It is classified as venture growth investor backed and is currently operating.
When was Third Pole founded?
Third Pole was founded in 2014. It employs 11 to 50 people.
Where is Third Pole based?
Third Pole is headquartered in Waltham, United States, in the North America region.
How does Third Pole make money?
Three revenue lines are on record. eNOcare™ Hospital Device Sales are the primary driver. The others are eNOfit™ Wearable/Outpatient Device Sales and NO Generation Technology Licensing.
Who are Third Pole's main competitors?
Emerging players on record are Aerogen, Pulmonx and Bellerophon Therapeutics. Broad incumbents are ResMed, Philips Respironics, United Therapeutics, Inogen and Mallinckrodt Pharmaceuticals (INO Therapeutics). Direct peers are Vero Biotech and Beyond Air.
Does Third Pole have an API?
No public API is recorded for Third Pole.
What industry is Third Pole in?
Third Pole's product category is Inhaled Nitric Oxide Therapy Devices. Its primary akta.pro industry code is HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories), with a secondary code of HLAHAGAK, Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers). Its NAICS code is 334510 and its SIC code is 3845.